In the present study, we confirmed that circulating levels of IL-6 and TNF-α are increased in patients with ACS concurrently with endothelial dysfunction, confirming not only the inflammatory theory of vulnerable plaque but also providing possible additional targets for therapy and the molecule-specific modification of the inflammatory cascade in the acute settings. The gene discussed is TNF; the disease is endothelial dysfunction.